Open an account

Zai Lab

ZLAB · HONG

$24.03+$1.99 (+9.03%)TodayMarket closed ·
Prev close $22.04

About ZLAB

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. The firm is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The firm has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The firm conducts its businesses within domestic and overseas markets.

Employees
1,194
Headquarters
Shanghai, Shanghai
Listed
Sep 28, 2020
Sector
Health Care
Industry
Biotechnology
Website
zailaboratory.com

ZLAB key statistics

Market cap
20.26B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
785.13K
Volume
3.69M
Open price
$23.19
High today
$24.54
Low today
$22.23
52 Week high
$28.75
52 Week low
$15.96

Zai Lab (ZLAB) at a glance

Zai Lab (ZLAB) last traded at $24.03, with a market cap of 20.26B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $22.23 and $24.54. The current price is 8.1% above the day's low and 2.1% below its high.

Volume so far is 3.69M shares, above the average of 785.13K shares a day.

Over the past year Zai Lab has ranged from $15.96 to $28.75, and now sits 63% of the way up that range.

Zai Lab met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.05 per share against an estimate of -$0.0658.

The average analyst price target is $29.31, 22.0% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 10 analystsAvg $29.31
Low
$20.21
Now
$24.03
High
$39.14

ZLAB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 25.8% on average.

  1. Q3 FY24: reported -$0.04 per share against an estimate of -$0.0816
  2. Q4 FY24: reported -$0.08 per share against an estimate of -$0.0714
  3. Q1 FY25: reported -$0.04 per share against an estimate of -$0.051
  4. Q2 FY25: reported -$0.04 per share against an estimate of -$0.0408
  5. Q3 FY25: reported -$0.03 per share against an estimate of -$0.0444
  6. Q4 FY25: reported -$0.05 per share against an estimate of -$0.0658
  7. Q1 FY26: reported -$0.05 per share against an estimate of -$0.0479
  8. Q2 FY26: reported -$0.05 per share against an estimate of -$0.0658

ZLAB news

  • Press releaseBusiness Wire

    Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

  • Press releaseBusiness Wire

    Zai Lab Announces $250 Million Private Placement

  • Press releaseBusiness Wire

    Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026

  • Press releaseBusiness Wire

    Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases

  • Zai Lab Reports Q2 2026 Results: Full Earnings Call Transcript

  • Press releaseBusiness Wire

    Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

  • Press releaseBusiness Wire

    Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

  • Press releaseBusiness Wire

    Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.